Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Goldinger · SciRah

Researcher profile · Semantic Scholar

S. Goldinger

Share profile

S. Goldinger — researcher profile on SciRah

h-index: 42
Works: 134
Citations: 13K

Most-cited papers

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
E. V. Van Allen, Diana Miao, B. Schilling, S. Shukla +18 more
2015Science2,643 citations Open access
Semantic Scholar
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf +32 more
2015The Lancet Oncology1,521 citations Open access
Semantic Scholar
Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients
David Liu, B. Schilling, Derek Liu, A. Sucker +32 more
2019Nature Medicine848 citations Open access
Semantic Scholar
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
E. V. Van Allen, N. Wagle, A. Sucker, D. Treacy +28 more
2014Cancer Discovery711 citations Open access
Semantic Scholar
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
L. Hofmann, A. Forschner, C. Loquai, S. Goldinger +24 more
2016European Journal of Cancer631 citations
Semantic Scholar
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
L. Zimmer, S. Goldinger, L. Hofmann, C. Loquai +24 more
2016European Journal of Cancer530 citations Open access
Semantic Scholar
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
P. Tumeh, M. Hellmann, O. Hamid, K. Tsai +30 more
2017Cancer immunology research512 citations Open access
Semantic Scholar
Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms
Douglas B. Johnson, A. Menzies, L. Zimmer, Z. Eroglu +23 more
2015European Journal of Cancer305 citations Open access
Semantic Scholar
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
E. V. Van Allen, N. Wagle, A. Sucker, D. Treacy +28 more
2013Cancer Discovery292 citations Open access
Semantic Scholar
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
R. Dummer, S. Goldinger, C. Turtschi, N. Eggmann +6 more
2014European Journal of Cancer290 citations
Semantic Scholar
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Y. Jansen, E. Rozeman, R. Mason, S. Goldinger +19 more
2019Annals of Oncology210 citations Open access
Semantic Scholar
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
S. Goldinger, P. Stieger, B. Meier, S. Micaletto +3 more
2016Clinical Cancer Research191 citations Open access
Semantic Scholar
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
L. Zimmer, S. Apuri, Z. Eroglu, L. Kottschade +16 more
2017European Journal of Cancer185 citations
Semantic Scholar
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Douglas B. Johnson, Wyatt J. McDonnell, Paula I. Ericsson-Gonzalez, R. Al-Rohil +29 more
2019Nature Medicine159 citations Open access
Semantic Scholar
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
F. Dimitriou, R. Krattinger, E. Ramelyte, M. Barysch +3 more
2018Current Oncology Reports157 citations
Semantic Scholar
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
S. Hogan, A. Courtier, P. Cheng, N. Jaberg-Bentele +12 more
2018Cancer immunology research132 citations Open access
Semantic Scholar
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
M. Tio, R. Rai, Ogochukwu M Ezeoke, J. McQuade +21 more
2018European Journal of Cancer118 citations Open access
Semantic Scholar
Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
U. Urner-Bloch, M. Urner, P. Stieger, N. Galliker +5 more
2014Annals of Oncology104 citations Open access
Semantic Scholar
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
M. Hecht, L. Zimmer, C. Loquai, C. Weishaupt +20 more
2015Annals of Oncology96 citations Open access
Semantic Scholar
Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
P. Cheng, O. Shakhova, D. Widmer, O. Eichhoff +10 more
2015Genome Biology94 citations Open access
Semantic Scholar
Derivation and validation of a prediction scale for response to PD-1 monotherapy.
Adi Nosrati, S. Goldinger, K. Tsai, Kimberly Loo +6 more
201692 citations
Semantic Scholar
Electrical Impedance Spectroscopy in Skin Cancer Diagnosis.
R. Braun, J. Mangana, S. Goldinger, L. French +2 more
2017Dermatologia clinica91 citations Open access
Semantic Scholar
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
S. Valpione, M. Carlino, J. Mangana, M. Mooradian +19 more
2018European Journal of Cancer83 citations Open access
Semantic Scholar
Sarcoid-like reactions in patients receiving modern melanoma treatment
F. Dimitriou, A. Frauchiger, Mirjana Urosevic-Maiwald, Mirjam C. Naegeli +7 more
2018Melanoma research77 citations Open access
Semantic Scholar
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
U. Urner-Bloch, Martin Urner, N. Jaberg-Bentele, A. Frauchiger +2 more
2016European Journal of Cancer73 citations Open access
Semantic Scholar
A review of serious adverse effects under treatment with checkpoint inhibitors
L. Heinzerling, S. Goldinger
2017Current Opinion in Oncology60 citations
Semantic Scholar
Developments in targeted therapy in melanoma.
Valerie C. Amann, E. Ramelyte, S. Thurneysen, R. Pitocco +4 more
2017European Journal of Surgical Oncology57 citations Open access
Semantic Scholar
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
J. Pham, A. Joshua, I. D. Da Silva, R. Dummer +1 more
2023Current Oncology Reports54 citations Open access
Semantic Scholar
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
B. Schilling, W. Sondermann, F. Zhao, K. Griewank +18 more
2014Annals of Oncology52 citations Open access
Semantic Scholar
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
S. Goldinger, K. Buder-Bakhaya, S. Lo, A. Forschner +36 more
2021European Journal of Cancer51 citations Open access
Semantic Scholar
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
S. Diem, F. Keller, R. Rüesch, S. A. Maillard +6 more
2016Journal of immunotherapy45 citations Open access
Semantic Scholar
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Reinhard Dummer, M. Duvic, J. Scarisbrick, Elise A. Olsen +9 more
2014Annals of Oncology43 citations Open access
Semantic Scholar
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati, K. Tsai, S. Goldinger, P. Tumeh +8 more
2017British Journal of Cancer42 citations Open access
Semantic Scholar
Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial.
S. Goldinger, Sharon Gobbi Bischof, R. Fink-Puches, C. Klemke +3 more
2016JAMA dermatology40 citations Open access
Semantic Scholar
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
B. Schilling, A. Martens, M. H. Geukes Foppen, C. Gebhardt +16 more
2019Cancer Immunology and Immunotherapy39 citations Open access
Semantic Scholar
Basal cell carcinomas in a tertiary referral centre: a systematic analysis
J. Dreier, P. Cheng, I. B. Alleman, A. Gugger +5 more
2014British Journal of Dermatology39 citations
Semantic Scholar
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
S. Bossart, S. Thurneysen, E. Rushing, K. Frontzek +6 more
2017The Oncologist35 citations Open access
Semantic Scholar
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
J. Mangana, P. Cheng, K. Schindler, B. Weide +13 more
2015PLoS ONE35 citations Open access
Semantic Scholar
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies
I. D. Da Silva, I. Glitza, L. Haydu, Romany A. N. Johnpulle +21 more
2019Pigment Cell & Melanoma Research34 citations Open access
Semantic Scholar
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
M. Hecht, F. Meier, L. Zimmer, B. Polat +21 more
2018British Journal of Cancer34 citations Open access
Semantic Scholar
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study
J. Drago, D. Lawrence, E. Livingstone, L. Zimmer +9 more
2019Melanoma research33 citations Open access
Semantic Scholar
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
L. Krähenbühl, S. Goldinger, J. Mangana, K. Kerl +6 more
2018Neoplasia31 citations Open access
Semantic Scholar
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
S. Knispel, M. Gassenmaier, A. Menzies, C. Loquai +35 more
2021European Journal of Cancer29 citations
Semantic Scholar
Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status
Anna L. Frauchiger, J. Mangana, M. Rechsteiner, H. Moch +4 more
2016British Journal of Dermatology29 citations
Semantic Scholar
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
S. Goldinger, Jeannine D. Rinderknecht, R. Dummer, F. Kuhn +10 more
2015Pharmacology Research & Perspectives29 citations Open access
Semantic Scholar
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
S. Goldinger, L. Zimmer, C. Schulz, S. Ugurel +7 more
2014European Journal of Cancer27 citations Open access
Semantic Scholar
A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
B. Izar, W. Sharfman, F. Hodi, D. Lawrence +13 more
2017Cancer Medicine26 citations Open access
Semantic Scholar
Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study
M. Kunz, Mirjana Urosevic-Maiwald, S. Goldinger, A. Frauchiger +10 more
2016Journal of the European Academy of Dermatology and Venereology26 citations Open access
Semantic Scholar
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
M. Hecht, L. Zimmer, C. Loquai, C. Weishaupt +20 more
201526 citations Open access
Semantic Scholar
Treatment of melanoma brain metastases
S. Goldinger, C. Panje, P. Nathan
2016Current Opinion in Oncology25 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Dummer×28
Invite
R. Dummer — researcher profile on SciRah
L. Zimmer×14
Invite
L. Zimmer — researcher profile on SciRah
D. Schadendorf×14
Invite
D. Schadendorf — researcher profile on SciRah
R. Gutzmer×13
Invite
R. Gutzmer — researcher profile on SciRah

×11

Invite

C. Loquai — researcher profile on SciRah

Invite

J. Mangana — researcher profile on SciRah

Invite

J. Hassel — researcher profile on SciRah

Invite

C. Berking — researcher profile on SciRah

C. Weishaupt×7

Invite

C. Weishaupt — researcher profile on SciRah

L. Heinzerling×7

Invite

L. Heinzerling — researcher profile on SciRah

Invite

A. Menzies — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah